LTR Pharma (ASX:LTP) has listed on the ASX with a ticker code of LTP. The company is a clinical stage biopharmaceutical company and pioneering a novel intranasal technology – SPONTAN® – designed to treat erectile dysfunction in 10 minutes or less. LTR Pharma says the benefit of its business model is a significantly reduced time to approval and lower cost, even when compared with traditional drug repurposing strategies. The global erectile dysfunction market is expected to generate revenue of more than $7 billion US dollars by the end of 2026 | Investor presentation: https://lnkd.in/gb3b5T3j #LTP #ASX #ASXstocks #stocks #ASXIPO ##LTRPharma #ED #erectiledysfunction #shorts
DY6
0.165
292.9%
HCF
0.055
-84.3%
1TT
0.002
100%
AOF
0.48
-45.8%
88E
0.002
100%
SMX
0.017
-43.3%
MMR
0.005
66.7%
BLZ
0.002
-33.3%
CML
0.16
45.5%
PAB
0.002
-33.3%
ICR
0.01
42.9%
AKN
0.006
-25%
PHL
0.01
42.9%
3PL
0.6
-21.1%
ADN
0.014
40%
AVE
0.004
-20%
EL8
0.29
31.8%
BYH
0.004
-20%
MVP
0.61
31.2%
MEG
0.008
-20%
PNT
0.017
30.8%
PUA
0.009
-18.2%
DTR
0.009
28.6%
PNN
0.059
-18.1%
HMY
0.635
25.7%
EMN
0.205
-18%
DTM
0.005
25%
PGH
0.9
-17.8%
OLI
0.005
25%
MNC
0.12
-17.2%
RRR
0.035
25%
1AI
0.005
-16.7%
VRL
0.016
23.1%
AZL
0.005
-16.7%
WC1
0.016
23.1%
SPX
0.005
-16.7%
JLL
0.41
20.6%
GBE
0.026
-16.1%
5EA
0.8
20.3%
TMB
0.027
-15.6%
